Top

Cancer Chemotherapy and Pharmacology

Published in:

01-04-2018 | Original Article

Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells

Authors: Jie Cui, Min-Cong Wang, Ya-Min Zhang, Ming-Zhi Ren, Shi-Xiong Wang, Ke-Jun Nan, Li-Ping Song

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2018

Abstract

Objective

To investigate the potential radiosensitization of S-1 and gefitinib in human non-small cell lung cancer (NSCLC) in vitro and in vivo.

Methods

The impact of radiation, 5-fluorouracil (5-Fu), and gefitinib on the proliferation and apoptosis of human NSCLC A549, H1299, H1975, and HCC827 cells was examined by MTT and flow cytometry. The effect of radiation, 5-Fu, and gefitinib on the clonogenicity of H1975 and HCC827 cells was determined by colony formation assay. The effect of radiation, 5-fluorouracil (5-Fu), and gefitinib on the EGFR, AKT, and ERK1/2 activation in H1975 cells was determined by Western blot. The therapeutic efficacy of radiation, S-1, and gefitinib in the growth of implanted H1975 tumors and the AKT activation in the tumors were examined in vivo and immunohistochemistry, respectively.

Results

Combination of radiation, 5-Fu, and gefitinib significantly inhibited the proliferation of H1975 cells and triggered their apoptosis, but not other NSCLC cells tested. The combination therapy significantly mitigated the clonogenicity and attenuated the activation of EGFR and AKT signaling in H1975 cells. Furthermore, combination of S-1, gefitinib, and radiation significantly inhibited the growth of implanted H1975 tumors in mice and remarkably reduced the AKT phosphorylation in the tumors.

Conclusions

Our data indicated that combination of S-1 and gefitinib significantly increased radiosensitivity of H1975 cells. The triple combination therapies may benefit patients with the EGFR T790M mutant NSCLC.

Rafiemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, Salehiniya H, Makhsosi BR, Moini A (2016) Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis 8(6):1094–1102. https://doi.org/10.21037/jtd.2016.03.91 CrossRef

Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792. https://doi.org/10.1056/NEJMoa044238 CrossRef

Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11):760–774. https://doi.org/10.1038/nrc2947 CrossRef

Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4(5):411–435PubMedPubMedCentral

Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32(34):3824–3830. https://doi.org/10.1200/jco.2014.56.7412 CrossRef

Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D, Kong R, Chen Z, Sun J (2017) Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment. Clin Transl Oncol. https://doi.org/10.1007/s12094-017-1723-1

Kawahara M (2014) Efficacy of S-1 in non-small cell lung cancer. Expert Opin Pharmacother 15(13):1927–1942. https://doi.org/10.1517/14656566.2014.945424 CrossRef

Niho S, Ohe Y, Ohmatsu H, Umemura S, Matsumoto S, Yoh K, Goto K (2017) Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study. Lung Cancer 108:66–71. https://doi.org/10.1016/j.lungcan.2017.02.018 CrossRefPubMed

Yamaguchi M, Toyokawa G, Ohba T, Sasaki T, Kometani T, Hamatake M, Hirai F, Taguchi K, Yamanaka T, Seto T, Takenoyama M, Sugio K, Ichinose Y (2013) Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. Ann Thorac Surg 96(5):1783–1789. https://doi.org/10.1016/j.athoracsur.2013.06.036 CrossRefPubMed

10.

Furuichi M, Muramatsu T, Shimamura M, Nishii T, Takeshita S, Ishimoto S, Morooka H, Sodeyama M, Sakurai K, Amano S, Ohmori I, Shiono M (2010) Treatment with S-1 and radiation therapy for advanced lung cancer invading chest wall. Gan To Kagaku Ryoho 37(1):119–122PubMed

11.

Xu Y, Zhang Y, Ma S (2011) EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 73(3):249–255. https://doi.org/10.1016/j.lungcan.2011.04.017 CrossRefPubMed

12.

Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J, Ongkeko WM (2008) Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 118(8):1372–1376. https://doi.org/10.1097/MLG.0b013e318172aae4 CrossRef

13.

Wang MC, Liang X, Liu ZY, Cui J, Liu Y, Jing L, Jiang LL, Ma JQ, Han LL, Guo QQ, Yang CC, Wang J, Wu T, Nan KJ, Yao Y (2015) In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in nonsmall cell lung cancer cell lines. Oncol Rep 33(1):239–249. https://doi.org/10.3892/or.2014.3583

14.

Zheng MH, Sun HT, Xu JG, Yang G, Huo LM, Zhang P, Tian JH, Yang KH (2016) Combining whole-brain radiotherapy with gefitinib/erlotinib for brain metastases from non-small-cell lung cancer: a meta-analysis. Biomed Res Int 2016:5807346. https://doi.org/10.1155/2016/5807346 PubMedPubMedCentral

15.

Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE (2011) Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res 17(15):5038–5047. https://doi.org/10.1158/1078-0432.ccr-11-0358 CrossRefPubMedPubMedCentral

16.

Soderlund K, Perez-Tenorio G, Stal O (2005) Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 26(1):25–32PubMed

17.

Toulany M, Rodemann HP (2015) Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Semin Cancer Biol 35:180–190. https://doi.org/10.1016/j.semcancer.2015.07.003 CrossRefPubMed

18.

Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4(6):761–767. https://doi.org/10.1097/JTO.0b013e3181a1084f CrossRef

19.

Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ (2014) Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88(4):947–954. https://doi.org/10.1016/j.ijrobp.2013.12.038 CrossRefPubMed

20.

Swaminath A, Wright JR, Tsakiridis TK, Ung YC, Pond GR, Sur R, Corbett TB, Okawara G, Levine MN (2016) A phase II trial of erlotinib and concurrent palliative thoracic radiation for patients with non-small-cell lung cancer. Clin Lung Cancer 17(2):142–149. https://doi.org/10.1016/j.cllc.2015.09.008 CrossRefPubMed

21.

Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS (2014) Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol 25(1):121–126. https://doi.org/10.1093/annonc/mdt516 CrossRefPubMedPubMedCentral

22.

Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T (2013) A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 85(1):163–169. https://doi.org/10.1016/j.ijrobp.2012.03.059 CrossRefPubMed

23.

Abu Lila AS, Moriyoshi N, Fukushima M, Huang CL, Wada H, Ishida T (2017) Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. Cancer Lett 400:223–231. https://doi.org/10.1016/j.canlet.2016.11.005 CrossRefPubMed

24.

Ferdous T, Harada K, Kin T, Harada T, Ueyama Y (2013) Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells. Int J Oncol 43(1):271–279. https://doi.org/10.3892/ijo.2013.1950 CrossRef

Title: Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells
Authors: Jie Cui
Min-Cong Wang
Ya-Min Zhang
Ming-Zhi Ren
Shi-Xiong Wang
Ke-Jun Nan
Li-Ping Song
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3539-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

A novel way to manage trastuzumab cardiotoxicity

Role of immunotherapy in bladder cancer: past, present and future

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer